FGFR2 and intrahepatic cholangiocarcinoma: Ten patients with intrahepatic cholangiocarcinoma and FGFR2 alterations were treated with an FGFR inhibitor (derazantinib or pemigatinib), with the latter now being approved by EMA in pretreated patients harboring FGFR2 fusions, and five patients received pembrolizumab (Fig. 3d).